Delay in intensifying treatment with insulin for many individuals with T2D is common, with fear of hypoglycaemia among patients and healthcare providers an important contributing factor.13 The problem of clinical inertia may be magnified in the context of older individuals.14 Treatment delay could place older individuals at greater risk of the microvascular and macrovascular complications of diabetes, as they often have less organ reserve and more comorbid conditions than younger individuals.15 The gene discussed is INS; the disease is diabetes mellitus.